WallStreetZenWallStreetZen

NASDAQ: LRMR
Larimar Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for LRMR

Based on 5 analysts offering 12 month price targets for Larimar Therapeutics Inc

Min Forecast
$5.00+30.89%
Avg Forecast
$9.60+151.31%
Max Forecast
$13.00+240.31%

Should I buy or sell LRMR stock?

Based on 5 analysts offering ratings for Larimar Therapeutics Inc.

Buy
Strong Buy
1 analysts 20%
Buy
4 analysts 80%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although LRMR's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates LRMR as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their LRMR stock forecasts and price targets.

LRMR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-14
lockedlocked$00.00+00.00%2026-08-05
lockedlocked$00.00+00.00%2026-07-02
lockedlocked$00.00+00.00%2026-06-30
lockedlocked$00.00+00.00%2026-05-27

1 of 1

Forecast return on equity

Is LRMR forecast to generate an efficient return?

Company
-142.24%
Industry
19.26%
Market
167.68%
LRMR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LRMR forecast to generate an efficient return on assets?

Company
-109.61%
Industry
23.46%
LRMR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LRMR earnings per share forecast

What is LRMR's earnings per share in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
-$1.40
Avg 2 year Forecast
-$1.13
Avg 3 year Forecast
-$0.67

LRMR revenue forecast

What is LRMR's revenue in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$43.6M
Avg 3 year Forecast
$170.1M

LRMR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LRMR$3.82$9.60+151.31%Buy
ARTV$8.09$39.00+382.08%Strong Buy
VOGX$26.57$48.50+82.54%Strong Buy
CYPH$3.73$3.25-12.87%Strong Buy
AGEN$8.70$26.33+202.68%Strong Buy
View Top Biotech Stocks

Larimar Therapeutics Stock Forecast FAQ

Is Larimar Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: LRMR) stock is to Buy LRMR stock.

Out of 5 analysts, 1 (20%) are recommending LRMR as a Strong Buy, 4 (80%) are recommending LRMR as a Buy, 0 (0%) are recommending LRMR as a Hold, 0 (0%) are recommending LRMR as a Sell, and 0 (0%) are recommending LRMR as a Strong Sell.

If you're new to stock investing, here's how to buy Larimar Therapeutics stock.

What is LRMR's earnings growth forecast for 2026-2028?

(NASDAQ: LRMR) Larimar Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.68%.

Larimar Therapeutics's earnings in 2026 is -$172,605,000.On average, 13 Wall Street analysts forecast LRMR's earnings for 2026 to be -$145,228,346, with the lowest LRMR earnings forecast at -$151,284,721, and the highest LRMR earnings forecast at -$136,346,355. On average, 13 Wall Street analysts forecast LRMR's earnings for 2027 to be -$116,941,022, with the lowest LRMR earnings forecast at -$171,032,867, and the highest LRMR earnings forecast at -$31,632,354.

In 2028, LRMR is forecast to generate -$69,321,084 in earnings, with the lowest earnings forecast at -$153,518,204 and the highest earnings forecast at -$7,635,396.

What is LRMR's revenue growth forecast for 2026-2028?

(NASDAQ: LRMR) Larimar Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.96%.

Larimar Therapeutics's revenue in 2026 is $0.On average, 12 Wall Street analysts forecast LRMR's revenue for 2026 to be $0, with the lowest LRMR revenue forecast at $0, and the highest LRMR revenue forecast at $0. On average, 13 Wall Street analysts forecast LRMR's revenue for 2027 to be $4,526,595,097, with the lowest LRMR revenue forecast at $471,316,885, and the highest LRMR revenue forecast at $17,943,699,708.

In 2028, LRMR is forecast to generate $17,673,604,072 in revenue, with the lowest revenue forecast at $11,779,286,226 and the highest revenue forecast at $30,269,410,183.

What is LRMR's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: LRMR) forecast ROA is -109.61%, which is lower than the forecast US Biotechnology industry average of 23.46%.

What is LRMR's Price Target?

According to 5 Wall Street analysts that have issued a 1 year LRMR price target, the average LRMR price target is $9.60, with the highest LRMR stock price forecast at $13.00 and the lowest LRMR stock price forecast at $5.00.

On average, Wall Street analysts predict that Larimar Therapeutics's share price could reach $9.60 by Sep 14, 2027. The average Larimar Therapeutics stock price prediction forecasts a potential upside of 151.31% from the current LRMR share price of $3.82.

What is LRMR's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: LRMR) Larimar Therapeutics's current Earnings Per Share (EPS) is -$1.39. On average, analysts forecast that LRMR's EPS will be -$1.40 for 2026, with the lowest EPS forecast at -$1.46, and the highest EPS forecast at -$1.31. On average, analysts forecast that LRMR's EPS will be -$1.13 for 2027, with the lowest EPS forecast at -$1.65, and the highest EPS forecast at -$0.30. In 2028, LRMR's EPS is forecast to hit -$0.67 (min: -$1.48, max: -$0.07).

What is LRMR's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: LRMR) forecast ROE is -142.24%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.